These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 21998335

  • 1. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 2. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):659-67. PubMed ID: 20033812
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 4. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB.
    Ann Surg Oncol; 2013 Oct 01; 20(11):3407-13. PubMed ID: 23943026
    [Abstract] [Full Text] [Related]

  • 6. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P.
    Clin Colorectal Cancer; 2013 Jun 01; 12(2):128-35. PubMed ID: 23276521
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.
    J Clin Oncol; 2013 Oct 10; 31(29):3664-72. PubMed ID: 24019539
    [Abstract] [Full Text] [Related]

  • 9. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.
    Cancer Chemother Pharmacol; 2011 Aug 10; 68(2):317-23. PubMed ID: 20972872
    [Abstract] [Full Text] [Related]

  • 10. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
    Kumar A, Peixoto RD, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Speers CH, Cheung WY.
    Clin Colorectal Cancer; 2015 Dec 10; 14(4):262-8.e1. PubMed ID: 26123496
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT.
    J Clin Oncol; 2005 Aug 20; 23(24):5635-43. PubMed ID: 16110022
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.
    Cancer; 2007 Mar 15; 109(6):1082-9. PubMed ID: 17265519
    [Abstract] [Full Text] [Related]

  • 16. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G.
    Br J Cancer; 2013 Apr 02; 108(6):1238-44. PubMed ID: 23481186
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE, Hong YS, Kim HJ, Kim KP, Kim SY, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Kim JH, Kim TW.
    Ann Surg Oncol; 2017 May 02; 24(5):1289-1294. PubMed ID: 27853901
    [Abstract] [Full Text] [Related]

  • 19. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.
    Jpn J Clin Oncol; 2013 Feb 02; 43(2):132-8. PubMed ID: 23204187
    [Abstract] [Full Text] [Related]

  • 20. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS, Yoo JH, Kim KH, Bae KB, Choi CS, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH.
    World J Surg Oncol; 2015 Feb 19; 13():64. PubMed ID: 25889520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.